SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 118 filers reported holding SAREPTA THERAPEUTICS INC in Q1 2014. The put-call ratio across all filers is 0.89 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $4,878,092 | +43.1% | 30,874 | +17.2% | 0.04% | +45.8% |
Q1 2024 | $3,409,329 | +48.5% | 26,335 | +10.6% | 0.02% | +41.2% |
Q4 2023 | $2,295,902 | -19.5% | 23,809 | +1.2% | 0.02% | -32.0% |
Q3 2023 | $2,851,095 | +4.0% | 23,520 | -1.7% | 0.02% | +13.6% |
Q2 2023 | $2,740,692 | -16.5% | 23,932 | +0.5% | 0.02% | -21.4% |
Q1 2023 | $3,283,111 | -17.0% | 23,820 | -22.0% | 0.03% | -20.0% |
Q4 2022 | $3,955,041 | +11.8% | 30,522 | -4.6% | 0.04% | +9.4% |
Q3 2022 | $3,537,000 | +13.7% | 31,999 | -22.9% | 0.03% | +28.0% |
Q2 2022 | $3,112,000 | -4.0% | 41,512 | +0.1% | 0.02% | +31.6% |
Q1 2022 | $3,241,000 | -14.1% | 41,490 | -0.9% | 0.02% | -5.0% |
Q4 2021 | $3,771,000 | +7.3% | 41,878 | +10.1% | 0.02% | -4.8% |
Q3 2021 | $3,516,000 | +16.7% | 38,023 | -1.9% | 0.02% | +16.7% |
Q2 2021 | $3,013,000 | -2.9% | 38,756 | -6.9% | 0.02% | -10.0% |
Q1 2021 | $3,103,000 | -40.4% | 41,646 | +36.4% | 0.02% | -39.4% |
Q4 2020 | $5,207,000 | +9.4% | 30,542 | -9.9% | 0.03% | -2.9% |
Q3 2020 | $4,761,000 | -24.1% | 33,901 | -13.3% | 0.03% | -30.6% |
Q2 2020 | $6,269,000 | +88.1% | 39,099 | +14.7% | 0.05% | +44.1% |
Q1 2020 | $3,333,000 | -37.1% | 34,079 | -17.1% | 0.03% | -15.0% |
Q4 2019 | $5,303,000 | +63.7% | 41,093 | -4.5% | 0.04% | +53.8% |
Q3 2019 | $3,240,000 | -46.9% | 43,022 | +7.1% | 0.03% | -48.0% |
Q2 2019 | $6,103,000 | +10.0% | 40,165 | -13.7% | 0.05% | +11.1% |
Q1 2019 | $5,550,000 | +5.5% | 46,565 | -3.5% | 0.04% | 0.0% |
Q4 2018 | $5,263,000 | -23.1% | 48,230 | +13.8% | 0.04% | 0.0% |
Q3 2018 | $6,847,000 | +4.3% | 42,392 | -14.6% | 0.04% | +2.3% |
Q2 2018 | $6,564,000 | +55.5% | 49,667 | -12.9% | 0.04% | +340.0% |
Q1 2018 | $4,222,000 | +16.1% | 56,996 | -12.8% | 0.01% | +11.1% |
Q4 2017 | $3,635,000 | -4.2% | 65,347 | -21.9% | 0.01% | 0.0% |
Q3 2017 | $3,796,000 | +34.7% | 83,717 | +0.2% | 0.01% | +28.6% |
Q2 2017 | $2,818,000 | +8.9% | 83,550 | -4.5% | 0.01% | 0.0% |
Q1 2017 | $2,588,000 | +10.0% | 87,473 | +2.0% | 0.01% | 0.0% |
Q4 2016 | $2,353,000 | -59.0% | 85,769 | -8.2% | 0.01% | -61.1% |
Q3 2016 | $5,737,000 | +142.9% | 93,410 | -24.6% | 0.02% | +157.1% |
Q2 2016 | $2,362,000 | -51.4% | 123,869 | -1.7% | 0.01% | -50.0% |
Q4 2015 | $4,864,000 | +128.4% | 126,065 | +90.0% | 0.01% | +100.0% |
Q3 2015 | $2,130,000 | +603.0% | 66,344 | +567.2% | 0.01% | +600.0% |
Q2 2015 | $303,000 | +91.8% | 9,944 | -16.4% | 0.00% | – |
Q1 2015 | $158,000 | -94.6% | 11,899 | -94.1% | 0.00% | -100.0% |
Q4 2014 | $2,932,000 | +10.1% | 202,670 | +60.6% | 0.01% | +16.7% |
Q3 2014 | $2,662,000 | -6.7% | 126,177 | +31.8% | 0.01% | -14.3% |
Q2 2014 | $2,852,000 | -3.7% | 95,748 | -22.4% | 0.01% | -12.5% |
Q1 2014 | $2,963,000 | -1.3% | 123,312 | -16.4% | 0.01% | -11.1% |
Q4 2013 | $3,003,000 | -41.8% | 147,444 | +35.0% | 0.01% | -52.6% |
Q3 2013 | $5,159,000 | +19.1% | 109,229 | -4.1% | 0.02% | +5.6% |
Q2 2013 | $4,332,000 | – | 113,840 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Evolutionary Tree Capital Management, LLC | 68,937 | $5,138,000 | 3.04% |
Avoro Capital Advisors LLC | 2,150,000 | $160,240,000 | 2.77% |
Casdin Capital, LLC | 550,000 | $40,992,000 | 1.22% |
TOBAM | 371,107 | $27,659,000 | 1.18% |
Ikarian Capital, LLC | 455,900 | $33,978,000 | 1.14% |
Eventide Asset Management | 697,156 | $51,959,000 | 0.77% |
FOX RUN MANAGEMENT, L.L.C. | 4,902 | $365,000 | 0.66% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 31,500 | $2,348,000 | 0.62% |
Sivik Global Healthcare LLC | 20,000 | $1,491,000 | 0.54% |
Rock Springs Capital Management LP | 328,750 | $24,502,000 | 0.54% |